BCG
10 clinical trials
2 abstracts
16 indications
Indication
HealthyIndication
TuberculosisIndication
COVID-19Indication
therapeutic vaccineIndication
BCGIndication
SARS-CoV-2Indication
InfectionIndication
Non-muscle-invasive Bladder CancerIndication
HIV infectionIndication
BCG vaccination reactionIndication
InfectionsIndication
InflammationIndication
Bladder CancerIndication
AllergyIndication
EczemaIndication
Respiratory Tract InfectionsClinical trial
A Phase 1a, Dose-finding, Open-label Trial Followed by a Phase 1b, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Tuberculosis Subunit Vaccine H107e/CAF®10b in AdultsStatus: Recruiting, Estimated PCD: 2026-05-01
Abstract
Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity.Org: Michigan Institute of Urology,
Clinical trial
A Feasibility Study of a Controlled Human Infection Model (CHIM) With Intradermal Bacillus Calmette-Guérin (BCG) Injection in MalawiStatus: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison PopulationStatus: Withdrawn, Estimated PCD: 2020-08-17
Clinical trial
COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin EnhancementStatus: Completed, Estimated PCD: 2022-06-04
Clinical trial
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South AfricaStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Long Term Assessment of Infectious Diseases and Immune Mediated Disorders After BCG (re)VaccinationStatus: Active (not recruiting), Estimated PCD: 2023-05-15
Clinical trial
Phase Ib Study of Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer (ABC Trial)Status: Completed, Estimated PCD: 2021-03-23
Clinical trial
A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in InfantsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult VolunteersStatus: Completed, Estimated PCD: 2019-05-09
Abstract
Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.Org: UWA Medical School, University of Western Australia & Linear Clinical Research, NHMRC Clinical Trials Centre, The University of Sydney, Fiona Stanley Hospital and Edith Cowan University,